henhaobio
Sign in

bioRxivCancer BiologyPreprint

Quantum CART (qCART), a piggyBac-based system for development and production of virus-free multiplex CAR-T cell therapy

Y.-C. Chen, W.-K. Hua, J. C. Hsu, P. S. Chang, K.-L. K. Wen, Y.-W. Huang, J.-C. Tsai, Y.-H. Kao, P.-H. Wu, P.-N. Wang, K.-F. Chen, W.-T. Liao, S. C.-Y. Wu

PDFDOI

Abstract

Chimeric antigen receptor T (CAR-T) cell therapy has the potential to transform cancer treatment. However, CAR-T therapy application is currently limited to certain types of relapsed/refractory B cell lymphomas. To unlock the full potential of CAR-T therapy, technologic breakthroughs will be needed in multiple areas, including optimization of autologous CAR-T development, shortening the innovation cycle, and further manufacturing advancement of next-generation CAR-T therapies. Here, we established a simple and robust virus-free multiplex Quantum CART system that seamlessly and synergistically integrates four platforms: 1. GTailor for rapid identification of lead CAR construct design, 2. Quantum Nufect for effective but gentle electroporation-based gene delivery, 3. Quantum pBac, featuring a virus-free transposon-based vector with large payload capacity and integration profile similar to retrovirus, and 4. iCellar for robust and high-quality CAR+ T memory stem cell expansion. This robust, virus-free multiplex Quantum CART system is expected to unleash the full potential of CAR-T therapy for treating diseases.

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.